9,10-dimethyl-1,2-benzanthracene has been researched along with picibanil in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horiuchi, R; Iino, Y; Owada, S; Sugamata, N; Tago, T; Yoshida, M | 1 |
| Iino, Y; Izuo, M; Ogawa, T; Takikawa, H; Yoshida, M | 1 |
| Chino, T; Mogi, M; Nakajima, J | 1 |
| Iino, Y | 1 |
4 other study(ies) available for 9,10-dimethyl-1,2-benzanthracene and picibanil
| Article | Year |
|---|---|
Effects of sequential and combined immuno-endocrine therapies using OK-432 (Picibanil) and tamoxifen on the growth of 7,12-dimethylbenz [alpha] anthracene-induced rat mammary carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Mammary Neoplasms, Experimental; Picibanil; Rats; Rats, Inbred Strains; Tamoxifen | 1991 |
Effects of OK-432 (Picibanil) on estrogen receptor levels and tamoxifen treatment in 7,12-dimethylbenz[a]anthracene-induced rat mammary cancers.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Biological Products; Female; Mammary Neoplasms, Experimental; Picibanil; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen | 1990 |
Inhibition by streptococcal immunopotentiator OK432 of lymph-node metastasis in hamster cheek-pouch carcinoma with enhancement of tumour necrosis factor-alpha and interleukin-6 in serum.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adjuvants, Immunologic; Animals; Antineoplastic Agents; Carcinogens; Carcinoma, Squamous Cell; Cheek; Cricetinae; Disease Models, Animal; Humans; Injections, Intraperitoneal; Interleukin-6; Lymphatic Metastasis; Male; Mesocricetus; Mouth Neoplasms; Picibanil; Tumor Necrosis Factor-alpha | 1996 |
Treatment of tamoxifen-refractory breast cancer--approach by animal models.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanes; Disease Models, Animal; Female; Mammary Neoplasms, Experimental; Mice; Mice, Nude; O-(Chloroacetylcarbamoyl)fumagillol; Picibanil; Prognosis; Rats; Receptors, Estrogen; Risk Assessment; Sesquiterpenes; Tamoxifen; Tegafur; Treatment Failure; Uracil | 2001 |